Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis.

Journal of controlled release : official journal of the Controlled Release Society - 10 Dec 2005

Yang Victor C, Naik Sarita S, Song Hui, Dombkowski Alan A, Crippen Gorden, Liang Jun F

Abstract excerpt

To resolve the bleeding risk associated with thrombolytic therapy, we have designed an approach, termed ATTEMPTS (Antibody Targeted Triggered Electrically Modified Prodrug Type Strategy), to deliver t-PA to the clot site in an inactive form and then trigger its conversion to the active form, so that it would selectively activate the clot bound plasminogen while alleviating the bleeding risk. This delivery system...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CHO Cells
Share to Drug Delivery Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Design

Share to Fibrinolytic Agents

Share to Heparin

Share to In Vitro Techniques

Share to Prodrugs

Share to Tissue Plasminogen Activator

Source

Identifiers

PMID: 16260060
DOI: 10.1016/j.jconrel.2005.09.027

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis.PMID 16260060Read ↗

RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice.Semantic proximity Read ↗

Improvement of the fibrinolytic activity, acid resistance and thermostability of nattokinase by surface charge engineering.Semantic proximity Read ↗

Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator.Semantic proximity Read ↗

Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis.Semantic proximity Read ↗

Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents.Semantic proximity Read ↗

Effective lysis of model thrombi by a t-PA mutant (A473S) that is resistant to alpha2-antiplasmin.Semantic proximity Read ↗

Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic strokeSemantic proximity Read ↗

The potential improvement of thrombolytic therapy by targeting with bispecific monoclonal antibodies: why they are used and how they are made.Semantic proximity Read ↗

Labeling of human clots in vitro with an active-site mutant of t-PA.Semantic proximity Read ↗

Biochemical and Immunological Properties of Engineered Low-Immunogenic Staphylokinases for Next-Generation Thrombolytic TherapySemantic proximity Read ↗

Redesigning t-PA for improved thrombolytic therapy.Semantic proximity Read ↗

Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.